leadf
logo-loader
viewBetterLife Pharma Inc
(
CSE:BETROTCQB:BETRF
)

BetterLife Pharma announces tie-up with Carleton University to study TD-0148A as treatment for depression

The company reckons the therapy will mimic the projected therapeutic potential of LSD without causing undesirable psychoactive dissociative side effects

BetterLife Pharma Inc -
BetterLife's CEO Dr Ahmad Doroudian said: "TD-0148A is a potential novel new therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment resistant severe depression and post-traumatic stress disorder"

BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) has said it is partnering up with Carleton University in Ottawa to study TD-0148A - a second-generation LSD molecule - to treat depression.

BetterLife reckons the therapy will mimic the projected therapeutic potential of LSD without causing undesirable psychoactive dissociative side effects. The university's head of neuroscience Dr Argel Aguilar-Valles and his team will work with BetterLife to test TD-0148A in both in vitro and in vivo models in the lab in a bid to understand the molecular mechanisms that underlie psychiatric and neurodevelopmental disorders.

READ: BetterLife Pharma hires Eurofins CDMO to manufacture LSD derivative TD-0148A

"We are delighted to have the opportunity to examine TD-0148A in our established animal depression models. The high rate of resistance to SSRI and other first-line treatments for major depressive disorder indicates an urgent unmet need for alternative anti-depressant treatments," said Dr Aguilar-Valles in a statement on Monday.

"LSD and other psychedelic drugs have been shown to have anti-depressant effects, but their hallucinogenic effects represent an undesirable side effect. Non-hallucinogenic derivatives of these drugs such as TD-0148A, represent a promising alternative."

BetterLife's CEO Dr Ahmad Doroudian added: "TD-0148A is a potential novel new therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant severe depression and post-traumatic stress disorder."

He said BetterLife’s goal was to bring this treatment to investigational new drug (IND) status and to the clinic "as soon as possible".

Betterlife is a life sciences company focused on developing next-generation psychedelic products to treat mental disorders.

Contact the author at giles@proactiveinvestors.com

Quick facts: BetterLife Pharma Inc

Follow
CSE:BETR

Price: 0.28 CAD

Market Cap: $23.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma’s Interferon alpha-2b Covid-19 trial in Chile enrolls...

BetterLife Pharma CEO Ahmad Doroudian joined Steve Darling from Proactive to share news their wholly owned subsidiary, Altum Pharmaceuticals Inc. and Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of Phase 1-2 randomized placebo-controlled study...

2 days, 12 hours ago

2 min read